Molecular residual disease testing offers earlier insight into cancer treatment response

In oncology, determining whether cancer has truly been eliminated after therapy is challenging because imaging and standard clinical criteria often miss low‑level disease. Molecular residual disease (MRD) assays detect circulating tumor DNA (ctDNA) – tiny fragments of tumor genetic material that appear in the bloodstream – providing a molecular signal of disease before it can be seen on scans.

When ctDNA becomes undetectable during or after treatment, known as ctDNA clearance, it can serve as an early indicator that a therapy is working. Tracking ctDNA dynamics gives researchers and clinicians a real‑time view of how a tumor is responding, often ahead of radiographic evidence.

For drug developers, this capability reshapes clinical trial design. By identifying molecular recurrence before radiographic relapse, sponsors can launch Treatment on MRD (TOMR) trials that enroll patients at an earlier disease stage, target tumors when the burden is low, and potentially extend the window for therapeutic intervention.

Overall, MRD testing promises a more precise and timely approach to evaluating cancer therapies, offering both patients and developers a clearer picture of treatment effectiveness before traditional methods can confirm it.